Stacey Jill Sukoff Rizzo Home Addres

University of Pittsburgh School of Medicine CURRICULUM VITAE 2020

BIOGRAPHICAL

Name: Stacey Jill Sukoff Rizzo Home Address: 2574 Corteland Drive Business Address: 100 Technology Drive Pittsburgh, PA 15241 556 Bridgeside Point I Home Phone: 1-860-772-7522 Pittsburgh, PA 15219 Email: [email protected] Business Phone: 1-412-383-3719

EDUCATION and TRAINING UNDERGRADUATE 1991-1995 Rutgers University, B.S. 1995 Animal Sciences New Brunswick, NJ, USA

GRADUATE 2008-2012 University College Ph.D. 2012 Neuroscience London, United Kingdom Advisor: Stephen J. Moss, Ph.D.

APPOINTMENTS and POSITIONS ACADEMIC 2019- Present Department of Neurobiology Associate Professor Department of Medicine – Aging Institute University of Pittsburgh Pittsburgh, PA USA

Preclinical Phenotyping Core Director University of Pittsburgh Pittsburgh, PA USA

NON-ACADEMIC 2014-2019 The Jackson Laboratory Associate Director, Center Bar Harbor, Maine, USA for Biometric Analysis Director, Mouse Neurobehavioral Phenotyping Facility

2011-2014 Pfizer Neuroscience Research Principle Research Scientist Cambridge, MA, USA

2010-2011 Pfizer Neuroscience Research Senior Research Scientist Groton, MA, USA

2003-2010 Wyeth Discovery Neuroscience Research Senior Research Scientist Princeton, NJ, USA 2001-2003 Aventis Pharmaceuticals Scientist Bridgewater, NJ, USA

1999-2001 Merck Research Laboratories Staff Biologist San Diego, CA, USA

1996-1999 Wyeth-Ayerst Research Scientist Princeton, NJ, USA

1995-1996 The Wistar Institute Research Technician Philadelphia, PA, USA

MEMBERSHIP in PROFESSIONAL and SCIENTIFIC SOCIETIES

Society for Neuroscience (SFN) 1996-present New York Academy of Sciences 2007-2010 International Behavioural and Neural Genetics Society (IBANGS) 2014-2016 International Behavioral Neuroscience Society (IBNS) 2015-present

HONORS Aventis Achievement Award 2002 Wyeth peer nominated achievement awards 2004,2005,2007 Wyeth Discovery Research Annual Meeting Oral Presentation Award 2005 Wyeth “Research Scientist of the Year” Award 2006

PUBLICATIONS

PEER REVIEWED REFEREED ARTICLES

1. Welmaker, G. S., Nelson, J. A., Sabalski, A. L., Potoski, J. R., Graziano, D., Kagan, M., Coupet, J., Dunlop, J., Mazandarani, H., Rosenzweig-Lipson, S., Sukoff, S., and Zhang, Y. Synthesis and 5- Hydroxytryptamine (5-HT) Activity of 2,3,4,4a-Tetrahydro-1H-Pyrazino[1,2-a]Quinoxalin-5- (6H)Ones and 2,3,4,4a,5,6-Hexahydro-1H-Pyrazino[1,2-a]Quinoxalines. Bioorganic & Medicinal Chemistry Letters, 2000, 10(17).

2. Brodkin, J., Busse, C., Sukoff, S. J., and Varney, M. A. Anxiolytic-like activity of the mGluR5 antagonist MPEP. A comparison with Diazepam and Buspirone. Pharmacology, Biochemistry, and Behavior, 2002 September; 73 (2): 359-366. 3. Maynard, K. I., Sukoff, S.J., Ji, Z., Wettstein, J.G., and Black, M.D. The acoustic startle reflex in Sprague-Dawley rats is altered by permanent middle cerebral artery occlusion.” Brain Research, 2005, 1032: 44-49. 4. Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, Sukoff S, Vogel RL, Stack G, Schechter L, Harrison BL, and Rosenzweig-Lipson S. WAY-163909 ((7bR,10aR)-1,2,3,4,8,9,10,10a- octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole); A Novel 5-HT2C Receptor Selective Agonist with Anorectic Activity. Journal of Pharmacol Exp Ther 2005 May;313(2):862-9. 5. Childers WE Jr., Abou-Gharbia MA, Kelly MG, Andree TH, Harrison BL, Ho DM, Hornby G, Huryn DM, Potestio L, Rosenzweig-Lipson SJ, Schmid J, Smith DL., Sukoff SJ, Zhang G, and Schechter L.E. Synthesis and Biological Evaluation of Benzodioxanylpiperazine Derivatives as Potent Serotonin 5-HT1A Antagonists: The Discovery Lecozatan. J. Med. Chem 2005 May 19; 48(10): 3467-70. 6. Brandt, M.R., Cummons, T., Sukoff, S.J., Potestio, L., and Rosenzweig-Lipson, S. Effects of the NMDA receptor antagonist perzinfotel (EAA-090) on chemically-induced thermal hypersensitivity. Journal of Pharmacology and Experimental Therapeutics 313(3):1379-1386, 2005 Jun. 7. Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafusco J, Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M, Barrett JE, Childers W. Lecozotan (SRA-333): A selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. Journal of Pharmacology & Experimental Therapeutics 314(3):1274-1289, 2005 Sep. 8. Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B, Schechter LE, Rizzo S, Rahman Z, Rosenzweig-Lipson S. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology 185(2):218-225, 2006 Apr. 9. Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg JE, Grauer S, Brennan J, Cryan JF, Sukoff Rizzo SJ, Dunlop J, Barrett JE, Marquis KL. Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology 192(2):159-170, 2007 Jun. 10. Rajarao SJ, Platt B, Sukoff SJ, Lin Q, Bender C, Nieuwenhuijsen BW, Ring RH, Rosenzweig-Lipson S, Beyer CE. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon. Neuropeptides 41(5):307-320, 2007 Oct. 11. Malberg J, Platt B, Sukoff Rizzo SJ, Lucki I, Schechter L, Rosenzweig-Lipson S. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 32(11):2360-2368, 2007 Nov. 12. Sukoff Rizzo SJ, Schechter LE, Rosenzweig-Lipson S. A novel approach for predicting antidepressant-induced sexual dysfunction in rats. Psychopharmacology 195(4):459-467, 2008 Jan. 13. Leonard SK, Dwyer JM, Sukoff Rizzo SJ, Platt B, Logue SF, Neal SJ, Malberg JE, Beyer CE, Schechter LE, Rosenzweig-Lipson S, Ring, RH. Pharmacology of Neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology 197(4):601-11, 2008 May.

14. Dwyer JM, Rizzo SJ, Neal SJ, Lin Q, Jow F, Arias RL, Rosenzweig-Lipson S, Dunlop J, Beyer CE. Acid sensing ion channel (ASIC) inhibitors exhibit anxiolytic-like activity in preclinical pharmacological models. Psychopharmacology (Berl). 2009 Mar;203(1):41-52. 15. Sukoff Rizzo SJ, Pulicicchio C, Malberg JE, Andree TH, Stack GP, Hughes ZA, Schechter LE, Rosenzweig-Lipson S. 5-HT1A receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats. Int J Neuropsychopharmacol. 2009 Sep;12(8):1045-53. 16. Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, Grauer S, Pulicicchio C, Resnick L, Rahman Z, Sukoff Rizzo SJ, Luo B, Beyer CE, Logue SF, Marquis KL, Hughes ZA, Rosenzweig-Lipson S. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology. 2010 Jan;58(1):69-77. 17. Kelly MP, Logue SF, Brennan J, Day JP, Lakkaraju S, Jiang L, Zhong X, Tam M, Sukoff Rizzo SJ, Platt BJ, Dwyer JM, Neal S, Pulito VL, Agostino MJ, Grauer SM, Navarra RL, Kelley C, Comery TA, Murrills RJ, Houslay MD, Brandon NJ. Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8457-62. 18. Childers WE Jr, Havran LM, Asselin M, Bicksler JJ, Chong DC, Grosu GT, Shen Z, Abou-Gharbia MA, Bach AC 3rd, Harrison BL, Kagan N, Kleintop T, Magolda R, Marathias V, Robichaud AJ, Sabb AL, Zhang MY, Andree TH, Aschmies SH, Beyer C, Comery TA, Day M, Grauer SM, Hughes ZA, Rosenzweig-Lipson S, Platt B, Pulicicchio C, Smith DE, Sukoff-Rizzo SJ, Sullivan KM, Adedoyin A, Huselton C, Hirst WD. The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists. J Med Chem. 2010 May 27;53(10):4066-84. 19. Dwyer JM, Platt BJ, Rizzo SJ, Pulicicchio CM, Wantuch C, Zhang MY, Cummons T, Leventhal L, Bender CN, Zhang J, Kowal D, Lu S, Rajarao SJ, Smith DL, Shilling AD, Wang J, Butera J, Resnick L, Rosenzweig-Lipson S, Schechter LE, Beyer CE. Preclinical characterization of BRL 44408: antidepressant- and analgesic-like activity through selective alpha2A-adrenoceptor antagonism. Int J Neuropsychopharmacol. 2010 Oct;13(9):1193-205. 20. Gilbert AM, Bursavich MG, Lombardi S, Adedoyin A, Dwyer JM, Hughes Z, Kern JC, Khawaja X, Rosenzweig-Lipson S, Moore WJ, Neal SJ, Olsen M, Rizzo SJ, Springer D. 3-(Pyridin-2-yl- ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies. Bioorg Med Chem Lett. 2011 Jan 1;21(1):195-9. 21. Sukoff Rizzo SJ, Leonard SK, Gilbert A, Dollings P, Smith DL, Zhang MY, Di L, Platt BJ, Neal S, Dwyer JM, Bender CN, Zhang J, Lock T, Kowal D, Kramer A, Randall A, Huselton C, Vishwanathan K, Tse SY, Butera J, Ring RH, Rosenzweig-Lipson S, Hughes ZA, Dunlop J. The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? J Pharmacol Exp Ther. 2011 Jul;338(1):345-52. 22. Hughes ZA, Neal SJ, Smith DL, Sukoff Rizzo SJ, Pulicicchio CM, Lotarski S, Lu S, Dwyer JM, Brennan J, Olsen M, Bender CN, Kouranova E, Andree TH, Harrison JE, Whiteside GT, Springer D, O'Neil SV, Leonard SK, Schechter LE, Dunlop J, Rosenzweig-Lipson S, Ring RH. Negative allosteric modulation of metabolic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology. 2013; 66:202-14. 23. Silverman JL, Smith DG, Rizzo SJ, Karras MN, Turner SM, Tolu SS, Bryce DK, Smith DL, Fonseca K, Ring RH, Crawley JN. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med. 2012 Apr 25;4(131):131ra51.

24. Sukoff Rizzo SJ, Neal SJ, Hughes ZA, Beyna M, Rosenzweig-Lipson S, Brandon NJ, and Moss SJ. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl Psychiatry. 2012 Dec 4;2:e199. doi: 10.1038/tp.2012.120. 25. Sukoff Rizzo SJ, Edgerton JR, Hughes ZA, Brandon NJ. Future Viable Models of Psychiatry Drug Discovery in Pharma. J Biomol Screen. 2013; 18(5):509-21. 26. Paumier KL, Sukoff Rizzo SJ, Berger Z, Chen Y, Gonzales C, Kaftan E, Li L, Lotarski S, Monaghan M, Shen W, Stolyar S, Vasilyev D, Zaleska M, Hirst WD, and Dunlop J. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson’s disease. PloS one. 2013; 8(8):e70274. 27. Diggle CP, Sukoff Rizzo SJ, Popiolek M, Hinttala R, Schülke JP, Kurian MA, Carr IM, Markham AF, Bonthron DT, Watson C, Sharif SM, Reinhart V, James LC, Vanase-Frawley MA, Charych E, Allen M, Harms J, Schmidt CJ, Ng J, Pysden K, Strick C, Vieira P, Mankinen K, Kokkonen H, Kallioinen M, Sormunen R, Rinne JO, Johansson J, Alakurtti K, Huilaja L, Hurskainen T, Tasanen K, Anttila E, Marques TR, Howes O, Politis M, Fahiminiya S, Nguyen KQ, Majewski J, Uusimaa J, Sheridan E, Brandon NJ. Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. American journal of human genetics. 2016; 98(4):735- 43. 28. Sukoff Rizzo SJ, Lotarski S, Stolyar P, McNally T, Arturi C, Roos M, Finley J, Reinhart V, and Lanz T. Behavioral characterization of striatal-enriched protein tyrosine phosphatase (STEP) knockout mice. Genes, Brain, and Behavior, Genes Brain Behav. 2014 Sep;13(7):643-52 doi: 10.1111/gbb.12169. 29. Gonzales C, Zaleska M, Riddell DR, Atchison KP, Robshaw A, Zhou H, and Sukoff Rizzo SJ. Alternative method of oral administration by peanut butter pellet formulation results in target engagement of BACE1 and attenuation of gavage-induced stress responses in mice. Gonzales C, Zaleska MM, Riddell DR, Atchison KP, Robshaw A, Zhou H, Sukoff Rizzo SJ. Pharmacology, biochemistry, and behavior. 2014; 126:28-35. 30. Asinof SK, Sukoff Rizzo SJ, Buckley AR, Beyer BJ, Letts VA, Frankel WN, Boumil RM. Independent Neuronal Origin of Seizures and Behavioral Comorbidities in an Animal Model of a Severe Childhood Genetic Epileptic Encephalopathy. PLoS genetics. 2015; 11(6):e1005347. 31. Onos KD, Sukoff Rizzo SJ, Howell GR, Sasner M. Toward more predictive genetic mouse models of Alzheimer's disease. Brain research bulletin. 2016; 122:1-11. 33. Sukoff Rizzo SJ, Crawley JN. Behavioral Phenotyping Assays for Genetic Mouse Models of Neurodevelopmental, Neurodegenerative, and Psychiatric Disorders. Annual review of animal biosciences. 2017; 5:371-389. 34. Korstanje R, Ryan JL, Savage HS, Lyons BL, Kane KG, Sukoff Rizzo SJ. Continuous Glucose Monitoring in Female NOD Mice Reveals Daily Rhythms and a Negative Correlation With Body Temperature. Endocrinology. 2017; 158(9):2707-2712. 35. Peng Y, Shinde DN, Valencia CA, Mo JS, Rosenfeld J, Truitt Cho M, Chamberlin A, Li Z, Liu J, Gui B, Brockhage R, Basinger A, Alvarez-Leon B, Heydemann P, Magoulas PL, Lewis AM, Scaglia F, Gril S, Chong SC, Bower M, Monaghan KG, Willaert R, Plona MR, Dineen R, Milan F, Hoganson G, Powis Z, Helbig KL, Keller-Ramey J, Harris B, Anderson LC, Green T, Sukoff Rizzo SJ, Kaylor J, Chen J, Guan MX, Sellars E, Sparagana SP, Gibson JB, Reinholdt LG, Tang S, Huang T. Biallelic mutations in the

ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy. Human Molecular Genetics. 2017; 26(24):4937-4950. 36. Harrison DE, Strong R, Alavez S, Astle CM, DiGiovanni J, Fernandez E, Flurkey K, Garratt M, Gelfond JAL, Javors MA, Levi M, Lithgow GJ, Macchiarini F, Nelson JF, Sukoff Rizzo SJ, Slaga TJ, Stearns T, Wilkinson JE, Miller RA. Acarbose improves health and lifespan in aging HET3 mice. Aging Cell. 2019 Apr;18(2):e12898. doi: 10.1111/acel.12898. Epub 2019 Jan 27. PubMed PMID: 30688027; PubMed Central PMCID: PMC6413665. 37. Sayed AA, Sher RB, Sukoff Rizzo SJ, Anderson LC, Patenaude KE, Cox GA. Functional rescue in a mouse model of congenital muscular dystrophy with megaconial myopathy. Hum Mol Genet. 2019 Aug 15;28(16):2635-2647. doi: 10.1093/hmg/ddz068. PMID: 31216357. 38. Graham LC, Weronika GA, Chun Y, Risacher S, Philip VM, Saykin AJ, Sukoff Rizzo SJ, Howell GR. Exercise prevents obesity-induced cognitive decline and white matter damage in mice. Neurobiology of Aging, Neurobiol Aging. 2019 Aug;80:154-172. doi: 10.1016/j.neurobiolaging.2019.03.018. Epub 2019 May 3. PMID: 31170535. 39. Onos KD, Uyar A, Keezer KJ, Jackson HM, Preuss C, Acklin CJ, O’Rourke R, Buchanan RA, Cossette TL, Sukoff Rizzo SJ, Soto I, Carter GW, Howell GR. Enhancing face validity of mouse models of Alzheimer’s disease with natural genetic variation. PLOS Genetics, PLoS Genet. 2019 May 31;15(5):e1008155. doi: 10.1371/journal.pgen.1008155. eCollection 2019 May. PMID: 31150388. 40. Lanz TA, Reinhart V, Sheehan S, Sukoff Rizzo SJ, Bove SE, James LC, Volfson D, Lewis DA, Kleiman RJ. Post-mortem transcriptional profiling reveals widespread increase in inflammation in schizophrenia: a comparison of prefrontal cortex, striatum and hippocampus among matched tetrads of controls with subjects diagnosed with schizophrenia, bipolar or major depressive disorder. Transl Psychiatry. 2019 May 23;9(1):151. doi: 10.1038/s41398-019-0492-8. PMID: 31123247.

OTHER NON-PEER REVIEWED PUBLICATIONS

Invited Book Chapters

1. Rizzo S.J.S. (2016) Repetitive Behavioral Assessments for Compound Screening in Mouse Models of Autism Spectrum Disorders. In: Proetzel G., Wiles M. (eds) Mouse Models for Drug Discovery. Methods in Molecular Biology, vol 1438. Humana Press, New York, NY 2. Sukoff Rizzo SJ, Silverman JL. Methodological Considerations for Optimizing and Validating Behavioral Assays. Current protocols in mouse biology. 2016; 6(4):364-379. 3. Sukoff Rizzo SJ, Anderson LC, Green TL, McGarr T, Wells G, Winter SS. Assessing Healthspan and Lifespan Measures in Aging Mice: Optimization of Testing Protocols, Replicability, and Rater Reliability. Current Protocols in Mouse Biology, 2018; 8(2):e45. 4. Sukoff Rizzo SJ, McTighe SM, McKinzie D. Genetic Background and Sex: Impact on Generalizability of Research Findings. In: Bespalov A. Michel M.C., Steckler T. (eds) Handbook of Experimental Pharmacology. Good Research Practice in Pharmacology and Experimental Life Sciences, Springer Series, 2019 Oct 9. doi: 10.1007/164_2019_282. [Epub ahead of print] PMID: 31595415.

Abstracts

1. Sukoff SJ, Katz LS. Effects of Tamoxifen, an estrogen antagonist, on the sexual behavior of testosterone-treated, castrated goats. Society for the Study of Reproduction; 1995 2. Rosenzweig-Lipson S, Kelly MG, Abrol S, Finn M, Sukoff SJ. Modification of the behavioral effects of D-Fenfluramine and MCPP by SB200646 in Rats and Monkeys. Society for Neuroscience; 1997 3. Rosenzweig-Lipson S, Sukoff SJ. Antagonism of the rate-decreasing effects of 8-OH-DPAT in Rats by 5-HT1A compounds varying in intrinsic activity. Society for Neuroscience; 1997 4. Rosenzweig-Lipson S, Abrol S, Brandsgaard R, Sukoff SJ. 5-HT1A/SSRI Interactions: Drug Discrimination and Food Intake. Serotonin 50th Anniversary; 1998; Princeton, NJ, USA. 5. Finn M, Sukoff SJ, Abrol S, Rosenzweig-Lipson S. Modification of the behavioral effects of fluoxetine by WAY100635 in rodents. Society for Neuroscience; 1998 6. Sukoff SJ, Rosenzweig-Lipson S. Fluoxetine does not modify WAY-100635 5-HT1A Antagonist Behavioral Effects in Rats. Society for Neuroscience; 1998 7. Finn M, Sukoff SJ, Rosenzweig-Lipson S. Anxiolytic and discriminative-stimulus effects of the neuroactive steroids CO 6-0549 and CO 2-6749 in pigeons. Society for the Stimulus Properties of Drugs; 1998. 8. Sukoff S, Rosenzweig-Lipson S. Comparison of the 5-HT2C Antagonist Properties of SB206553 and RS-102221 in Rats. Behavioral Pharmacology Society; 1999. 9. Sukoff SJ, Ji Z, Wettstein JG, Maynard KI, Black MD. Focal cerebral ischemia impairs the acoustic startle reflex response in Sprague-Dawley Rats. Society for Neuroscience; 2002. 10. Kehne JH, Hoffman D, Gallo J, Logue S, Sukoff SJ, Wettstein JG, Lenox RH. Marked enhancement of acoustic startle reflexes in rats co-administered corticotrophin releasing factor and the Alpha2 Adrenergic receptor Antagonist, Yohimbine. The American College of Neuropsychopharmacology; 2002. 11. Pangalos MN, Smith DL, Rosenzweig-Lipson S, Sukoff S, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Harder JA, Womack MD, Buccafusco JJ, Terry AV, Hoebel B, Rada P, Kelly M, Abou- Gharbia M, Barrett JE, Chlders W, Schechter LE. The novel 5-HT1A receptor antagonist SRA-333 demonstrates precognitive properties in nonhuman primates. Neuropsychopharmacology 29(S1):S233-S234, December 2004. 12. Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff S, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Harder J. A novel selective 5-HT1A receptor antagonist with procognitive properties in nonhuman primates: SRA-333. Fundamental & Clinical Pharmacology 18:151(S1), July 2004. 13. Pangalos MN, Smith DL, Rosenzweig-Lipson S, Sukoff S, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Harder JA, Womack MD, Buccafusco JJ, Terry AV, Hoebel B, Rada P, Kelly M, Abou- Gharbia M, Barrett JE, Chlders W, Schechter LE. SRA333: A novel 5-HT1A receptor antagonist with procognitive properties in nonhuman primates. Neurobiology of Aging 25:S187-S188. July 2004. 14. Schechter, Smith DL, Rosenzweig-Lipson S, Sukoff S, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Harder JA, Womack MD, Buccafusco JJ, Terry AV, Rada P, Kelly M, Abou-Gharbia M, Barrett JE, Chlders W. Pharmacological profile of selective 5-HT1A receptor antagonist with

procognitive properties in nonhuman primates: SRA-333. International Journal of Neuropsychopharmacology. 7:S291. June 2004. 15. Beyer CE, Rizzo SS, Dwyer J, Lin Q, Schechter LE, Rosenzweig-Lipson S, Ring RH. Anxiolytic-like activity of oxytocin: Behavioral and neurochemical profile in rodent models of neuropsychiatric disorders. Neuropeptides 42(4):484. Aug 2008. 16. Sukoff Rizzo SJ, Hughes ZA, Neal S, Antal I, Ring RH, Kennedy JD, Moss SJ, and Rosenzweig-Lipson S. The Pro-Inflammatory Cytokines IL-6 and IL-1β appear to be Distinct in Their Roles in Centrally Mediating Depressive-Like and Sickness Behaviors in Rodents. Program No. 60.10. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009. Online. 17. Sukoff Rizzo SJ, Neal SJ, Hughes ZA, Rosenzweig-Lipson S, Brandon N, and Moss SJ. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of treatment resistant depression. Program No. P.75. Anxiety and Depression: 21st Neuropharmacology Conference. Washington DC November 10, 2011. 18. Sukoff Rizzo SJ, Neal SJ, Rolsma M, Stephenson DT, Ring RH, and Smith DG. Comparative behavioral phenotypes and cognitive assessment of autism relevant mouse strains: BTBR T+tf/J, C58/J, and Fmr1 KO. Society for Neuroscience Annual Meeting Abstracts, 2011. 19. Silverman JL, Karras MN, Turner SM, Tolu SS, Sukoff Rizzo SJ, Bryce DK, Smith DL, Smith DG, Ring RH, Crawley JN. mGluR5 blockade reverses autism-relevant phenotypes in the BTBR mouse model of autism. Society for Neuroscience Annual Meeting Abstracts, 2011. 20. Bryce DK, Sukoff Rizzo SJ, Mpoy MC, Ring RH, Smith DG. Effects of d-amphetamine and chlordiazepoxide on sociability and repetitive and exploratory behavior in the BTBR T+tf/J mouse model of autism. Society for Neuroscience Annual Meeting Abstracts, 2011. 21. Hughes ZA, Neal SJ, Smith DL, Rizzo SJS, Pulicicchio CM, Lotarski S, Bryce D, Lu S, Dwyer JM, Olsen M, Bender CN, Kouranova E, Springer D, Li D, O’Neil SV, Andree TH, Whiteside GT, Dunlop J, Brandon NJ, Schechter LE, Leonard SK, Rosenzweig-Lipson S, Ring RH. Broad spectrum activity of the mGluR5 negative allosteric modulator GRN-529 in preclinical anxiolytic-antidepressant, and analgesic models suggests the potential efficacy in treatment resistant depression. Current Neuropharmacology Meeting Abstracts No.82. Vol.9:29. Sep 2011. 22. Gonzales C, Zaleska MM, Riddell DR, Atchison KP, Robshaw A, and Rizzo SJ. Attenuation of stress- induced corticosterone in mice by a self-administration oral dosing procedure as an alternative to oral gavage. Society for Neuroscience Annual Meeting Abstracts, 2012. 23. Stolyar P, Zhu A, Eudy R, Lotarski S, Rizzo S, Chen L, Kuszpit K, Currier G, Zasadny K, M. Skaddan, Coelho R, Fan K, Schmidt C, Zaleska MM. Behavioral Characterization and Brain Glucose Metabolism Evaluation via PET Imaging in 6-7.5 Month Old Q175 Knock In Mouse Model of Huntington’s Disease. Society for Neuroscience Annual Meeting Abstracts, 2012. 24. Sukoff Rizzo SJ, Neal SJ, Roos M, Hughes ZA, Rosenzweig-Lipson S, Moss SJ, Brandon NJ. Depressive-like phenotype in transgenic mice with overexpression of IL-6 in the CNS. American College of Neuropsychopharmacology Annual Meeting Abstracts 2012. 25. McTighe SM, Pletcher M, Arturi C, Stolyar P, Sukoff Rizzo SJ, Reinhart VL, Hughes ZA, and Smith DG. Characterization of the impact of the innate Disc1 truncation on the BTBR mouse model of autism. Society for Neuroscience Annual Meeting Abstracts, 2013.

26. Popiolek M, Sukoff Rizzo SJ, Diggle CP, Carr IM, Markham AF, Bonthron DT, Pysden K, Reinhart V, James LC, Vanase-Frawley MA, Schuelke J-P, Charych E, Allen M, Harms J, Strick C, Sheridan E, and Brandon NJ. Loss of striatal pde10a causes chorea in humans. Society for Neuroscience Annual Meeting Abstracts, 2013. 27. Sukoff Rizzo SJ, Lanz TA, Lu G, Shao A, Yu X, O’Neill SM, and Kozak R. Modafinil fails to improve neonatal PCP-induced cognitive deficits in rats. Society for Neuroscience Annual Meeting Abstracts, 2013. 28. Stolyar P, Sukoff Rizzo SJ, Chappie T, Schmidt CJ. Evidence for muscarinic M4 receptor mediated inhibition on the influence of antipsychotic-like behavioral effects of haloperidol and the phosphodiesterase 10 inhibitor MP10 in rats. Society for Neuroscience Annual Meeting Abstracts, 2013. 29. Paumier KL, Rizzo SJ, Berger Z, Chen Y, Gonzales C, Kaftan E, Li L, Lotarski S, Shen W, Stolyar P, Vasilyev D, Zaleska M, Dunlop J, Hirst WD. The effects of trehalose in the A53T mouse model of Parkinson’s Disease. Cell Transplantation Meeting Abstract 22(5):912. 2013. 30. Modi ME, Reim D, Schmeisser MJ, Boechers TM, Sukoff Rizzo SJ, and Buhl DL. Shank2 Mutation in a Rat Model Induces Behavioral, Molecular and Electrophysiological Alterations Consistent with an ASD-like Phenotype. International Society for Autism Research Annual Meeting Abstracts, 2014. 31. Stolyar P, Arturi C, Volfson D, Lotarski S, Sukoff Rizzo SJ, Zaleska MM. Evaluation of prophylactic treatment with the phosphodiesterase 10 inhibitor MP10 on cognitive and behavioral assessments in the Q175 knock-in mouse model of Huntington’s disease. Society for Neuroscience Annual Meeting Abstracts, 2014. 32. Ward KM, Chen LG, Zhang L, Smith D, Chappie T, Schmidt C, Grimwood S, O’Connor R, Rizzo S, Schildknegt K. Development of novel PET ligands PF-04831704 and PF-06327104 for PDE10A. Schizophrenia Research Meeting Abstract No. 545, 2014. 153(S1):S104-S105. 33. Sukoff Rizzo SJ, Wells G, Burrill S, Ryan J, Anderson LC, Krebs MP, Nishina PM, Wiles MV. S. J. The neurobehavioral phenotypes of the C57BL/6NJ substrain are not altered by genetic rescue of the Crb1rd8 retinal degeneration mutation. Society for Neuroscience Annual Meeting Abstracts, 2015. 34. Joshi S, Sethi M, Striz M, Cole N, Ryan J, Lhamon ME, Agarwal A, Sukoff Rizzo SJ, Denegre JM, Braun RE, Fardo DW, Donohue KD, Chesler EJ, Svenson KL, O’Hara BF. Improved Sleep related Gene Ontologies through analysis of KOMP2 sleep phenotyping data and gene expression studies. Society for Neuroscience Annual Meeting Abstracts, 2015. 35. Sethi M, Joshi S, Striz M, Cole N, Ryan J, Lhamon ME, Agarwal A, Sukoff Rizzo SJ, Denegre JM, Braun RE, Fardo DW, Donohue KD, Chesler EJ, Svenson KL, O’Hara BF. Phenotyping sleep-wake traits in inbred and knockout mice from the KOMP2 population to identify potential genes influencing sleep. Society for Neuroscience Annual Meeting Abstracts, 2015. 36. Dickson PE, Wilcox T, Ndukum J, Clark J, Bubier JA, Rizzo SJ, Crabbe JC, Denegre JM, Svenson KL, Braun RE, Kumar V, Chesler EJ. Identification of addiction-relevent genes using high-throughput drug naïve behavioral screens in the knock out mouse project (KOMP). Society for Neuroscience Annual Meeting Abstracts, 2015.

37. Liegner A, William D, Rizzo S, Haskins A, Buchanan J. Establishing a functional model of mouse muscle injury and recovery. Medicine and Science in Sports and Exercise meeting Abstract No. 3166, May 2016. 48(5):901-902. 38. O’Hara BF, Sethi M, Joshi S, Striz M, Cole N, Ryan J, Rizzo S, Lhamon ME, Agarwal A, Denegre JM, Braun RE, Kumar V, Donohue KD, Sunderam S, Chesler EJ, Svenson KL. Noninvasive sleep monitoring in large scale screening of mouse knockouts (komp2) produces high hit rate with implications for sleep and behavioral studies. Society for Neuroscience Annual Meeting Abstracts, 2016. 39. Kumar V, Lee D, Philip V, Clark J, Svenson K, Rizzo S, Braun RE, Chesler EJ. Integrated analysis of the Jackson Laboratory knockout mouse project 2 (KOMP2) data. Society for Neuroscience Annual Meeting Abstracts, 2016. 40. Frankel WN, McGarr TC, Sukoff Rizzo S, Boumil RM, Petri S. Tmem151b, a novel seizure susceptibility gene encoding a putative ER protein. Society for Neuroscience Annual Meeting Abstracts, 2016. 41. Onos KD, Keezer KJ, Acklin CJ, Jackson HM, Sukoff Rizzo SJ, Sasner M, Carter GW, Chesler EJ, Lamb BT, Howell GR. Identifying genetic modifiers of Alzheimer’s disease-relevant phenotypes. Society for Neuroscience Annual Meeting Abstracts, 2016. 42. Sasner M, Morgan J, Goodwin L, Cheng K, Sukoff Rizzo SJ, Mingorance A. A novel inducible mouse model of Dravet syndrome. Society for Neuroscience Annual Meeting Abstracts, 2016. 43. Sasner M, Carter GW, Howell G, Rizzo SJ, Williams HM, Preuss C, Wang X, Philip V, Ananda G, Uyar A, Onos K, Logsdon B, Omberg L, Mangravite LM, Lamb BT, Territo P, Oblak AL, Saykin AJ, Nho K, Shen L. Model Organism Development and Evaluation for Late-Onset Alzheimer’s disease: MODEL-AD. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, Volume 13 , Issue 7 , P1280 - P1281. AD/PD Conference 2017. 44. Onos KD, Keezer KJ, Acklin CJ, Jackson HM, Cossette TL, O’Rourke R, Sukoff Rizzo SJ, Howell GR. Genetic Background is a Significant Driver of Alzheimer’s Disease Associated Phenotypes. International Behavioral Neuroscience Annual Meeting Abstracts, 2017. 45. Sukoff Rizzo SJ, Gagnon L, Olsen A, Leonardo M, Dodd R, Wilcox T, Roy T, Dickson P, Bogue M, Reinholdt L, Philip VM, Pratt CH, McClung CA, Logan RW, Tarantino M, Jentsch JD, Chesler EJ. High throughput phenotyping of addiction related traits in genetically diverse mouse populations. Society for Neuroscience Annual Meeting Abstracts, 2017. 46. Green TL, McGarr T, Winter SS, Anderson LC, Sukoff Rizzo SJ. Comprehensive longitudinal evaluation of aging-related phenotypes of frailty, neurosensory, motor, and cognitive measures in C57BL/6J mice. Society for Neuroscience Annual Meeting Abstracts, 2017. 47. Oblak A, Garter G, Howell GR, Logsdon B, Mangravite L, Nho K, Omberg L, Onos KD, Philip V, Preuss C, Sukoff Rizzo SJ, Sasner M, Shen L, Saykin AJ, Territo P, Uyar A, Williams H, Lamb BT. Model-ad: Genetic models of late-onset Alzheimer’s disease. Society for Neuroscience Annual Meeting Abstracts, 2017. 48. Territo PR, Sukoff Rizzo SJ, Onos KD, Meyer JA, Peters J, Persohn S, McCarthy B, Riley A, Quinney S, Jones D, Sasner M, Howell GR, Williams H, Oblak A, Lamb BT. Preclinical drug screening in new generation Alzheimer’s disease mouse models: The MODEL-AD Consortium Strategy. Society for Neuroscience Annual Meeting Abstracts, 2017.

49. Sukoff Rizzo SJ, Onos KD. Lack of generalization of strain and sex across behaviors – data from the founder strains of the collaborative cross and diversity outbred mouse populations. International Behavioral Neuroscience Society Annual Meeting Abstracts, 2017. 50. Carter G, Howell G, Lamb B, Territo P, Mangravite L, Saykin A, Sasner M, Rizzo S, Williams H, Oblak A. Creating the Next Generation of Animal Models for Alzheimer’s Disease in MODEL-AD. Alzheimer's Association International Conference Annual Meeting Abstracts, 2017. 51. Onos KD, Keezer K, Acklin C, Jackson H, Cossette T, O'Rourke R, Sukoff Rizzo SJ, Howell, G. Genetic background is a significant driver of Alzheimer’s disease associated phenotypes. International Behavioral Neuroscience Society Annual Meeting Abstracts, 2017. 52. Green TL, Winter SS, Viands E, Little G, Anderson LC, Harrison DE, Sukoff Rizzo SJ. Aging dependent changes across behavioral phenotypes vary with sex and strain in genetically diverse mouse populations. International Behavioral Neuroscience Society Annual Meeting Abstracts, 2018. 53. Sukoff Rizzo SJ, Anderson LC, McGarr T, Green T, Howell GR, Onos K. Behavioral characterization of genetically diverse mouse populations: Implications for improving translation from mouse to human. International Behavioral Neuroscience Society Annual Meeting Abstracts, 2018. 54. Williams HM, Oblak AL, O’Rourke R, Buchanan R, Keezer KJ, Ingraham C, Figueiredo L, Logsdon B, Sukoff Rizzo SJ, Carter GW, Howell G, Lamb BT, Sasner M. Characterizing the APOE4/Trem2*R47H Mouse Model for Late Onset Alzheimer’s Disease. Alzheimer's Association International Conference Annual Meeting Abstracts, 2018. 55. Sukoff Rizzo SJ, Quinney SK, Onos KD, Keezer KG, Jones DR, Masters AR, Metzger IF, Meyer JA, Peters J, Persohn SC, McCarthy BR, Riley AA, Sasner M, Howell G, Williams H, Oblak AJ, Lamb BL, Territo PR. The MODEL-AD consortium preclinical testing pipeline: pharmacokinetics and pharmacodynamics of prophylactic treatment with leviteracetam on the 5XFAD mouse model of Alzheimer’s disease. Alzheimer's Association International Conference Annual Meeting Abstracts, 2018. 56. Lamb BL, Oblak A, Williams H, Baglietto-Vargas D, Wood M, Mortazavi A, Green K, Carter G, Rizzo S, Territo P, Sasner M, MacGregor G, Howell G, Tenner AJ, LaFerla F. MODEL-AD: Late-Onset Alzheimer’s Disease Models. Alzheimer's Association International Conference Annual Meeting Abstracts, 2018. 57. Oblak A, Carter G, Howell G, Sukoff Rizzo SJ, Sasner M, Territo P, Williams H, Lamb B, Mortazavi A, Wood M, MacGregor G, Tenner A, Green K, LaFerla F. MODEL-AD: Characterization of Familial ADModels (5xFAD, APP/PS1, hTau, 3xTg-AD). Alzheimer's Association International Conference Annual Meeting Abstracts, 2018. 58. Sasner M, Williams H, Oblak A, Keezer K, O’Rourke R, Saykin A, Rizzo S, Carter G, Lamb B, Howell G. Novel mouse models of late-onset Alzheimer’s disease based on GWAS. Alzheimer's Association International Conference Annual Meeting Abstracts, 2018. 59. SJ Sukoff Rizzo, KD Onos, KJ Keezer, SK Quinney, DR Jones, AR Masters, IF Metzger, JA Meyer, J Peters, SC Persohn, BR McCarthy, AA Bedwell, M Sasner, G Howell, H Williams, AJ Oblak, BL Lamb, and PR Territo. Preclinical screening strategy of the MODEL-AD consortium: Evaluation of the pharmacokinetics and pharmacodynamics of treatment with levetiracetam. Society for Neuroscience Annual Meeting Abstracts, 2018.

60. Anderson LC, LaRue K, Wray C, Sukoff Rizzo SJ. Hands-on Workshop on Improving Rigor and Reproducibility in Preclinical Behavioral Testing. Society for Neuroscience Annual Meeting Abstracts, 2018. 61. C. Biesdorf, P.R. Territo, S.J.S. Rizzo, K.D. Onos, K.J. Keezer, D.R. Jones, A.R. Masters, I.F. Metzger, J.A. Meyer, J. Peters, S. Persohn, B.R. McCarthy, A.A. Bedwell, M. Sasner, G. Howell2, H. Williams, A.L. Oblak, B.T. Lamb, S.K. Quinney. The Model-AD Consortium Preclinical Testing Pipeline: Pharmacokinetics Of Verubecestat In The 5xfad Mouse Model Of Alzheimer’s Disease. American Society for Clinical Pharmacology and Therapeutics Annual Meeting Abstracts, 2019. 62. S. Rizzo, S. Quinney, K. Onos, K. Keezer, L. Haynes, D. Jones, A. Masters, C. Biesdorf De Almeida, J. Meyer, J. Peters, S. Persohn, A. Bedwell, D. McKinzie, M. Sasner, G. Howell, H. Williams, A. Oblak, B. Lamb, P. Territo. Evaluation of chronic treatment with levetiracetam on pharmacokinetics and pharmacodynamics in 5XFAD mice. The 14th International Congress on Alzheimer’s and Parkinson’s Disease (AD/PD) Meeting Abstracts Lisbon, Portugal, 2019. 63. Oblak A, Williams H, Carter G, Sukoff Rizzo S, Sasner M, Territo P, Howell G, Lamb B. Deep phenotyping of the 5XFAD mouse model using the MODEL-AD pipeline. The 14th International Congress on Alzheimer’s and Parkinson’s Disease (AD/PD) Meeting Abstracts Lisbon, Portugal, 2019. 64. Oblak A, Carter G, Howell G, Sukoff Rizzo S, Sasner M, Territo P, Williams H, Lamb B, Mortazavi A, Wood M, Forner S, MacGregor G, Tenner A, Green K, LaFerla F. Models of late onset Alzheimer’s Disease: The MODEL-AD Consortium. The 14th International Congress on Alzheimer’s and Parkinson’s Disease (AD/PD) Meeting Abstracts Lisbon, Portugal, 2019. 65. Sasner M, Oblak A, Williams H, Rizzo S, Territo P, Howell G, Lamb B. Characterization of a novel mouse model expressing APOE4 and TREM2R47H for furthering the understanding of late onset Alzheimer’s disease. The 14th International Congress on Alzheimer’s and Parkinson’s Disease (AD/PD) Meeting Abstracts Lisbon, Portugal, 2019. 66. PR Territo, SK Quinney, C Biesdorf, AR Masters, KD Onos, L Haynes, KJ Keezer, DR Jones, JA Meyer, J Peters, SC Persohn, BR McCarthy, AA Riley, M Sasner, G Howell, H Williams, D McKinzie, AJ Oblak, BL Lamb, and SJ Sukoff Rizzo. Critical evaluation of the pharmacokinetics of verubecestat in aged 5XFAD mice. Alzheimer's Association International Conference Annual Meeting Abstracts, 2019. 67. Carter GW, Pandey RS, Kotredes KP, Preuss C, Williams H, Territo P, Oblak A, Lamb B, Rizzo S, Sasner M, Howell G. Multi-Phenotype Comparison of an Apoe4.Trem2*R47H Mouse Model and Human Late-Onset Alzheimer’s Disease. Society for Neuroscience Annual Meeting Abstracts, 2019. 68. Oblak A, Williams H, Kotredes K, Sasner M, Sukoff Rizzo SJ, Carter GW, Howell GR, Preuss C, Uyar A, Pandey RS, Ingraham C, Soni D, Jadhavi J, Tsai AP-Y, Territo PR, Logsdon B, Lamb BT. Modeling Trem2 variants in mice. Society for Neuroscience Annual Meeting Abstracts, 2019. 69. Sukoff Rizzo SJ, Onos KD, Keezer K, Haynes L, Williams H, Quinney SK, Masters A, Biesdorf De Almeida C, Bedwell AA, Meyers JA, Ingraham C, Peters J, Persohn SA, Speedy R, Figueiredo L, Eldridge K, Sasner M, Oblak A, Lamb B, Carter GW, Territo PR. Transcriptomic analysis of chronic levetiracetam treatment in aged 5XFAD mice: Relationship with pharmacokinetics and pharmacodynamics. Society for Neuroscience Annual Meeting Abstracts, 2019.

PROFESSIONAL ACTIVITIES TEACHING

2002-2007 Rutgers, The State University of New Jersey, Department of Animal Sciences . Adjunct Faculty, Instructor for 3 lectures and 2 labs (undergraduate level, ~ 30 students; spring semesters) 2014-2018 Annual Short Course on the Genetics of Addiction The Jackson Laboratory, Bar Harbor, ME . Graduate, post-doc trainees, and junior faculty participants (~20 students) . Course faculty, 1 lecture/year, town-hall discussion panel 2014-2018 Short Course on Medical and Experimental Mammalian Genetics, Mouse Clinic . Graduate, post-doc trainees, junior faculty and CME participants (~ 50 attendees); 1 session/year 2014 The Mouse as Model System for Biomedicine Bates College Short Course, The Jackson Laboratory, Bar Harbor, ME . Undergraduate (~ 20 students) 1 lecture/year 2016-2018 Workshop on Neurogenetics Tools, The Jackson Laboratory, Bar Harbor, ME . Graduate, post-doc trainees, and junior faculty (~ 25 attendees); 2 lectures/year 2016-2017 Annual Workshop on the Pathology of Mouse Models of Human Disease, The Jackson Laboratory, Bar Harbor, ME . Graduate, post-doc trainees, and junior faculty (~ 25 attendees); 2 lectures/year 2016-2017 21st Century Mouse Genetics Short Course, The Jackson Laboratory, Bar Harbor, ME . Graduate, post-doc trainees, and junior faculty (~ 25 attendees); 2 lectures/year 2017 Principles and Techniques in Mouse Behavioral Phenotyping and Pharmacology, The Jackson Laboratory, Bar Harbor, ME . Course Director; 6 lectures and 5 labs . Graduate, post-doc trainees, and junior faculty (10 attendees) 2018-present Principles and Techniques for Improving Preclinical Translation in Alzheimer’s Disease, The Jackson Laboratory, Bar Harbor, ME . R13 Conference Grant (PI: Rizzo) . Course Director; 3 lectures and 2 labs . Graduate, post-doc trainees, and junior faculty (20 attendees)

Fellow Teaching: 2016-2018 Dr. Kristen Onos, PhD, Postdoctoral Fellow, The Jackson Laboratory 2020-present Dr. Takeshi Murai, PhD, Postdoctoral Fellow, University of Pittsburgh

Mentoring:

Visiting Scientist Trainees Jan 2015, Oct 2017 Dr. Chun-fang Huang, PhD, National Laboratory Animal Center, Taiwan Jan 2016 Dr. Marcia Hart, PhD, Assistant Professor, University of Missouri June 2016 Dr. Adam Liegner, MD, Maine Medical Center Research Institute Sept-Oct 2016 Dr. Sarah Stephenson, PhD, Postdoctoral Fellow, Murdoch Research Institute, Australia Sept 2017 Dr. Ross Cardarelli, PhD, Postdoctoral Fellow, Tufts University School of Medicine, Boston

Sept 2017 Ms. Anna Nathanson, BS, Research Associate, Tufts University School of Medicine, Boston Oct 2017 Dr. David Braun, PhD, Postdoctoral Fellow, University of Kentucky Oct 2017 Dr. George Sutphin, PhD, Assistant Professor, University of Arizona Oct 2017 Ms. Shu Hsuan Hung, Technologist Researcher, National Laboratory Animal Center, Taiwan Oct 2017 Mr. Mark Sanderson, Sr. Research Assistant, Welcome Trust Sanger Institute, UK Oct 2017 Ms. Hope Dang, Assistant Staff Scientist, University of Arizona Oct 2017 Mr. Taylor Lyles, PhD Student, Texas Tech University Health Science Center Oct 2017 Ms. Jennifer Black, Research Study Technician, Charles River Laboratories, Boston Oct 2017 Ms. Anna Stauffer, Research Coordinator, Florida Atlantic University Jan 2018 Ms. Victoria DeLeon, Research Associate, Shock Center, University of Texas San Antonio Jan 2018 Ms. Vanessa Martinez, Research Lab Technician, Strong Lab, University of Texas San Antonio

RESEARCH

Current Grant Support: Grant Number Grant Title Role in Project Years Inclusive Source Amount 1P50DA039841 Center for Systems Core PI: 8/15/2016- $366,534 Neurogenetics of Addiction %15 effort only 4/30/2021 1R13AG060708- Improving Preclinical PI: 5% effort 09/01/2018– $147,417 01 Translation in Alzheimer’s 08/31/2021 Disease U54 AG05434503 The IU/JAX Alzheimer’s Co-I: 20% 9/1/19 - Subaward Disease Precision Models effort 8/31/2020 $334,052 Center Preclinical Testing Core U54 AG05434503 The IU/JAX Alzheimer’s Co-I: 5% effort 9/1/19 - Subaward Disease Precision Models 8/31/2020 $22,906 Center Disease Modeling Core U54 AG05434503 The IU/JAX Alzheimer’s Co-I: 5% effort 9/1/19 - Subaward Disease Precision Models 8/31/2020 $23,095 Center Administrative Core 5U54AG054345- The IU/JAX Alzheimer’s Co-I: 15% 6/15/19 - Subaward 03S6 Disease Precision Models effort 3/31/2020 $171,936 Center PTC Transition Supplement PACS1 Syndrome Characterization of Mouse PI: 5% effort 4/1/2019- $94,134 Research Models of PACS1 Syndrome 4/30/2020 Foundation 1U54AG065181- IUSM Alzheimer’s Disease Co-I: 15% 9/30/2019- Subaward 01 Drug Discovery Center effort 8/31/2024 $108,900

1U54AG065187- Open Drug Discovery Center Co-I: 10% 9/30/2019- Subaward 01 for Alzheimer’s Disease effort 8/31/2024 $966,163

Prior Grant Support: N/A

Other research related activities

Patents

1. Sukoff Rizzo SJ, Schechter LE, and Rosenzweig-Lipson S. Effects of Substances on Sexual Function. International Patent WO 2006/124259 A1.

2. Sukoff Rizzo SJ, Rosenzweig-Lipson SJ, Childers WE, Kelly M, and Schechter LE. Serotonergic agents for treating sexual dysfunction. International Patent WO 2007/081374 A1.

Grant Reviews Member, NIH Drug Discovery for the Nervous System Study Section 2018-2022

Ad-hoc Reviewer: Tufts Clinical and Translational Science Institute (CTSI) Pilot Studies Program 2019

Ad-hoc Reviewer: Prader-Wili Syndrome Foundation Grant Program 2019

Journal Reviews Ad-hoc Reviewer for several international scientific journals, including: Neuron, Genes Brain Behavior, Learning and Memory, International Journal of Developmental Neuroscience, Nature Neuroscience, Behavioral Brain Research, Neuropharmacology, Pharmacology Biochemistry and Behavior, Journal of Neuroscience

Review Editor, Frontiers in Behavioral Neuroscience 2019

CURRENT RESEARCH INTERESTS  Aging, Alzheimer’s Disease, Neurodegenerative diseases and cognitive disorders  Genetically diverse animal models, mouse models of late onset sporadic Alzheimer’s Disease, marmosets as models for aging and Alzheimer’s Disease  Behavioral pharmacology and drug discovery for Alzheimer’s disease and Aging, and related comorbidities

INVITED SEMINARS

Local Presentations

May 2015 Translational Approaches to Studying Human Behaviors in Mice APS Healthcare 6th Annual Meeting, Augusta, Maine

May 2016 Translational Approaches for Studying Human Diseases in Mice APS Healthcare 7th Annual Meeting, Augusta, Maine

Sept 2016 Using Mice to Study Human Diseases Women in Government, The Jackson Laboratory, September 2016

May 2017 Panel Speaker – Careers Discussion The Whole Scientist Workshop, The Jackson Laboratory, Bar Harbor, Maine

March 2019 Translational Approaches to Studying Human Behaviors in Mice Bridgeside Research Forum, University of Pittsburgh

Dec 2019 Translational Approaches to Studying Human Behaviors in Mice Developmental Biology Department Symposia, University of Pittsburgh

Regional Presentations

July 2013 Role of IL-6 in Depressive Disorders: Behavioral characterization and evidence in animal models. Drexel University College of Medicine

April 2016 Translational Approaches to Studying Human Behaviors in Mice University of Missouri

Feb 2018 Improving Preclinical Translation in Modeling Alzheimer’s Disease University of Kentucky Sanders-Brown Center on Aging

May 2018 Improving Preclinical Translation and Reproducibility in Modeling Alzheimer’s Disease. Indiana University School of Medicine, Scientific Symposium

May 2019 Selection and Use of Mouse Models to Examine Biology and Therapeutic Potential University of Washington Alzheimer’s Disease Research Center, Scientific Symposium

Dec 2019 Improving Preclinical Translation in Alzheimer’s Disease Duquesne University

National Presentations

Oct 2015 Improving Experimental Reproducibility and Translation with Mouse Models for Autism. JAX Webinar Meet the Expert Series, October 2015

July 2018 MODEL-AD Preclinical Efficacy Testing and Training Resources. National Institutes of Aging collaborative meeting with the Alzheimer’s Association, Annual Alzheimer’s Associating International Conference, Chicago IL, USA

Nov 2018 Translation of behavioral assays in animal models to human cognition – challenges and opportunities. Alzheimer’s Association Business Consortium Translational Animal Models Think Tank. Washington DC, USA

July 2019 Improving Preclinical to Clinical Translation in Alzheimer’s Disease: The MODEL-AD Preclinical Testing Pipeline NIA-Alzheimer’s Association Meeting, Los Angeles, CA, USA

International Presentations

Aug 2015 The future of precision medicine: The Jackson laboratory’s Center for Biometric Analysis. German Mouse Clinic, Munich, Germany.

June 2017 Lack of generalization of strain and sex across behaviors: Data from the founder strains of the collaborative cross and diversity outbred mouse populations. International Behavioral Neuroscience Society, Hiroshima, Japan

May 2019 Improving Translation in Animal Models: The Science, Art, & Anecdotes International Society for Autism Research (INSAR), Montreal, Canada

June 2019 Improving Preclinical Translation in Alzheimer’s disease Research International Behavioral Neuroscience Society, Cairns, Australia

July 2019 Improving Preclinical Translation in Alzheimer’s disease Research The Florey Institute, Melbourne, Australia

July 2019 The Science, Art, & Anecdotes of Behavioral Testing: Improving Reproducibility and Translation in Animal Models National Laboratory for Animal Research, Taipei, Taiwan

July 2019 Translational Approaches for Studying Human Behaviors in Mice National Laboratory for Animal Research, Taipei, Taiwan

SERVICE

International Behavioral Neuroscience Society (IBNS) 2016-present

- Co-Chair, Education and Training Committee (IBNS) 2017 - Chair, Education and Training Committee (IBNS) 2018 - Past Chair and Member, Education and Training Committee (IBNS) 2019 - Member, Finance Committee 2019

Alzheimer’s Disease Cooperative Study 2017-present - Advisory Board Member, Compound Selection Committee Prader-Wili Syndrome Foundation 2017-present - Advisory Board Member, Preclinical Animal Models Working Group

Member, European Quality in Preclinical Data Stakeholder Group (EQIPD) 2018-present Innovative Medicine Initiative (IMI)

Alzheimer’s Association International Conference (AAIC) 2019, 2020 - Member, Scientific Program Committee

University of Pittsburgh Alzheimer’s Disease Faculty Search Committee 2019-present

National Service Member, NIH Drug Discovery for the Nervous System Study Section 2018-2022